Relevancia clínica del oncogén K-ras en cáncer de colon, experiencia en una población mexicana

Cunningham, 2010, Colorectal cancer, Lancet, 375, 1030, 10.1016/S0140-6736(10)60353-4 Tirado-Gómez, 2008, Epidemiologia del cáncer de colon y recto, Gaceta Onco Mex, 7, 3 Pérez, 2006, Gastrointestinal cancer in four medical centers in Mexico City. A 25-year study, Rev Gastroenterol Mex, 71, 460 Moran, 2010, Differential colorectal carcinogenesis: Molecular basis and clinical relevance, World J Gastrointest Oncol, 2, 151, 10.4251/wjgo.v2.i3.151 Heinemann, 2008, Clinical relevance of EGFR and K-ras status in colorectal cancer treated with monoclonal antibodies directed against the EGFR, Cancer Treat Rev, 39, 262 Shen, 2011, Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients, World J Gastrointest Oncol, 17, 808 Jiang, 2009, Assessment of K-ras mutations, Cancer, 115, 3609, 10.1002/cncr.24434 Hayes, 2000, New comprehensive denaturing-gradient-gel electrophoresis assay for K-ras mutation detection applied to parafin-embedded tumors, Genes Chromosomes Cancer, 29, 309, 10.1002/1098-2264(2000)9999:9999<::AID-GCC1037>3.0.CO;2-F Kressner, 1998, Ki-Ras mutations and prognosis in colorectal cancer, Eur J Cancer, 34, 518, 10.1016/S0959-8049(97)10111-3 Martínez-Garza, 1999, Frequency and clinicopathology associations of K-ras mutation in colorectal cancer in a Northwest Mexican population, Dig Dis, 17, 225, 10.1159/000016940 Yuan, 2010, K-ras gen mutation in colorectal cancer and its clinicopathologic significance, Zhongua Waike Zazhi (Chin J Surg), 48, 1247 Calderillo, 2008, Quimioterapia adyuvante en cáncer de colon, Gaceta Onco Mex, 7, 34 Petrelli, 2013, KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: A pooled analysis of 12 published trials, Med Oncol, 30, 1, 10.1007/s12032-013-0650-4 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 Bokemeyer, 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study, Ann Oncol, 22, 1535, 10.1093/annonc/mdq632 Arrington, 2012, Prognostic and predictive roles of KRAS mutations in colorectal cancer, Int J Mol Sci, 13, 12153, 10.3390/ijms131012153 Hartman, 2012, Mutant allele-specific imbalance modulates prognostic impact of K-ras mutations in colorectal adenocarcinoma and is associated with worse overall survival, Int J Cancer, 131, 1810, 10.1002/ijc.27461 Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 Bazan, 2002, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Ann Oncol, 13, 1438, 10.1093/annonc/mdf226 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Eng J Med, 359, 1757, 10.1056/NEJMoa0804385 Tejpar, 2008, Relationship of efficacy with K-ras status (wild-type or mutant) in patients with irinotecan-refractory metastasis colorectal cancer treated with irinotecan and escalating doses of cetuximab: The EVEREST experience, J Clin Oncol, 26, 4003, 10.1200/jco.2008.26.15_suppl.4001